Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 25.05.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
25.05.23MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings110NEWS RELEASE - REGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings IRVINE, CA, and HERSTAL, BELGIUM...
► Artikel lesen
25.05.23SPINEWAY: Strengthening of the cash position thanks to new financing403Press release Ecully, May 25, 2023 - 8 a.m. Strengthening of the cash position in support of the Group's developments "Without compromising on its values, purpose or strategy, the Spineway...
► Artikel lesen
25.05.23Vivesto AB: Interim report for the period January 2023 - March 2023146SIGNIFICANT EVENTS DURING THE FIRST QUARTERContinued focus of the operations towards research and development, including a reduction in staff and overall improvement in cost control, has contributed...
► Artikel lesen
25.05.23PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation109Ecully, May 25th, 2023 PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation PCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex...
► Artikel lesen
25.05.23Exela Technologies, Inc.: Exela Technologies Named a Leader in NelsonHall's Healthcare Payer Operational Transformation NEAT Vendor Evaluation 2023132IRVING, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. ("Exela" or the "Company") (NASDAQ: XELA, XELAP), a global business process automation ("BPA") leader, announced the Company...
► Artikel lesen
25.05.23Wireless Telecom Group, Inc.: Wireless Telecom Group Announces the Sale of the Company to Maury Microwave, Inc.122Shareholders to Receive $2.13 Per Share in Cash Parsippany, New Jersey, USA, May 25, 2023 (GLOBE NEWSWIRE) -- Wireless Telecom Group, Inc. (NYSE American: WTT) (the "Company" or "WTT"), a leading...
► Artikel lesen
25.05.23Byggfakta Group Nordic HoldCo AB: Bulletin from Annual General Meeting234The following resolutions were passed at the Annual General Meeting (the "AGM") of BYGGFAKTA GROUP Nordic HoldCo AB (publ) ("Byggfakta" or the "Company") held today, on 25 May 2023. Adoption of income...
► Artikel lesen
25.05.23Xintela AB: Interim Report January - March 2023340Summary of the interim reportThe "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-3480.First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before...
► Artikel lesen
25.05.23Zentalis Pharmaceuticals Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting272Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7%...
► Artikel lesen
25.05.23American Rebel Holdings Inc: American Rebel Announces New Value Line Safes and Highlights Q1 Results846Dramatic Increases in Revenue and Narrowing of Net Loss Due to Champion Acquisition Nashville, TN, May 25, 2023 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) - America's Patriotic...
► Artikel lesen
25.05.23Regeneron Pharmaceuticals, Inc.: Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma28271% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also...
► Artikel lesen
25.05.23Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting275MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens...
► Artikel lesen
25.05.23Relay Therapeutics, Inc.: Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008428CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...
► Artikel lesen
25.05.23Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 229Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended...
► Artikel lesen
25.05.23NVIDIA Announces Upcoming Events for Financial Community176SANTA CLARA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NVIDIA will present at the following events for the financial community: BofA Securities 2023 Global Technology ConferenceTuesday, June 6, 9:20...
► Artikel lesen
25.05.23Cue Biopharma, Inc.: Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting270As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable...
► Artikel lesen
25.05.23PDS Biotechnology Corporation: PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA (pembrolizumab) for Head and Neck Cancer Patients281Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
► Artikel lesen
25.05.23Urbanfund Corp.: Report on Financial Results for the Three Months Ended March 31, 202397TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) ("Urbanfund" or the "Company"), confirmed today that the Company has...
► Artikel lesen
25.05.23Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals706DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical...
► Artikel lesen
25.05.23Costco Wholesale Corporation Reports Third Quarter and Year-to-Date Operating Results for Fiscal 2023172ISSAQUAH, Wash., May 25, 2023 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation ("Costco" or the "Company") (Nasdaq: COST) today announced its operating results for the third quarter (twelve weeks)...
► Artikel lesen
Seite:  Weiter >>